All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Breaking News: Diagnosis and management of AML in adults – 2017 ELN recommendations from an international expert panel
Bookmark this article
A group of 21 outstanding international experts in the field of Acute Myeloid Leukemia (AML) have commented on the 2010 European LeukemiaNet (ELN) recommendations for diagnosis and management of AML in adults, and provided an up-to-date version for 2017. The expert panel included many members of the AGP Global Steering Committee. The recommendations, based on recent evidence- and opinion-based clinical experiences, included: a revision of the ELN genetic categories, a proposal for a response category based on Minimal Residual Disease (MRD) status, and criteria for progressive disease. These recommendations were required in light of the therapeutic advancements of novel anti-leukemic agents and the discovery of the different families of genetic mutations within AML.
The ELN works in association with the AGP Global Steering Committee and the AGP Secretariat to provide an online educational platform for academic researchers and clinicians treating AML patients worldwide.
We will be providing more in-depth expert opinions on these seminal recommendations, so please stay posted.
The full article can be found published in Blood.
- Döhner H. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2016: DOI:10.1182/blood-2016-08-733196.
More about...
Your opinion matters
15 votes - 79 days left ...
Newsletter
Subscribe to get the best content related to AML delivered to your inbox